Clinical Trial Modernization Act
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Clinical Trial Modernization Act (H.R. 8412) was a bill introduced in the 118th Congress aimed at updating and improving the processes related to clinical trials. Although the official summary and full text are not available, the bill was referred to the House Subcommittee on Health before it ultimately failed or expired. The legislation falls under the health policy area and likely intended to address modernization efforts in clinical trial procedures, potentially impacting regulatory frameworks, data collection, or trial efficiency.
H.R. 8412 sought to modernize clinical trial processes but did not advance beyond subcommittee referral and expired without enactment.
- The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health.
- No official summary or full text is publicly available, limiting detailed analysis of provisions.
- The bill status is marked as failed or expired, indicating it did not pass into law.
['Clinical researchers and institutions conducting clinical trials', 'Pharmaceutical and biotechnology industries involved in drug development', 'Regulatory agencies overseeing clinical trial processes', 'Patients and healthcare providers potentially benefiting from improved clinical trial outcomes']
['Lack of publicly available full text and summary limits understanding of implementation requirements and costs.', 'Unclear authority or oversight mechanisms due to missing detailed provisions.', 'Potential tradeoffs between modernization efforts and regulatory compliance or patient protections cannot be assessed.']
The bill was introduced in the House and referred to a relevant subcommittee but did not progress further. It is part of ongoing legislative efforts to update health-related regulatory frameworks, specifically targeting clinical trial processes, within the broader health policy domain.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Potential improvements in clinical trial efficiency and data quality if modernization provisions were implemented.', 'Possible shifts in regulatory workload or resource allocation within health agencies.', "Changes in the pharmaceutical and biotech sectors' approach to clinical trial design and execution."]
The absence of an official summary and full bill text significantly limits the ability to conduct a thorough transparency and oversight analysis. Monitoring future legislative proposals in this area should prioritize availability of detailed texts to ensure informed public and stakeholder engagement.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.